Table 4.

The relationship between cumulative drug dose and nonalcoholic fatty liver disease

Exposure	Model 1 HR (95% CI)	Model 2 HR (95% CI)	Model 3 HR (95% CI)	Model 4 HR (95% CI)	Model 5 HR (95% CI)
Cumulative dose (per 100 mg*months increase)	0.926 (0.918–0.934)	0.924 (0.916–0.932)	0.923 (0.915–0.931)	0.923 (0.915–0.931)	0.923 (0.915–0.931)

Model 1: Unadjusted (univariate analysis).

Model 2: Adjusted for age, sex, smoking status, alcohol consumption, and duration of hypertension.

Model 3: Model 2 plus additional adjustments for systolic blood pressure, diastolic blood pressure, BMI, waist circumference, diabetes mellitus, dyslipidemia, and coronary heart disease.

Model 4: Model 3 plus further adjustments for GGT, serum creatinine, uric acid, triglyceride, HDL-C, fasting blood glucose, and HbA1c.

Model 5: Model 4 plus adjustments for the use of antidiabetic medications, lipid-lowering agents, and antihypertensive drugs.

CI, confidence interval; GGT, gamma-glutamyl transferase; HbA1c, glycosylated hemoglobin; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio.